Concord Biotech receives USFDA approval for sclerosis treatment drug

received marketing approval for teriflunomide tablets, used for the treatment of patients with relapsing forms of multiple sclerosis, from the United States Food and Drug Administration (USFDA). The Teriflunomide tablets have a market size of approximately $402 million in the United States of America and a global market size of about $908 million, according to IQVIATM. The market size of this tablet presents significant opportunities for expansion in the US and the global market, Concord said.